Prodotto aggiunto correttamente al carrello.

discount label
H-SLLMWITQV^-OH
Visualizzare in 3D

Biosynth logo

H-SLLMWITQV^-OH

Rif. 3D-PP46378

Dimensione non definitaPrezzo su richiesta
Consegna stimata in Stati Uniti, il Lunedì 16 Dicembre 2024

Informazioni sul prodotto

Nome:
H-SLLMWITQV^-OH
Sinonimi:
  • NH2-Ser-Leu-Leu-Met-Trp-Ile-Thr-Gln-Val^-OH
Descrizione:

Peptide H-SLLMWITQV^-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-SLLMWITQV^-OH include the following: Position-Scanning Peptide Libraries as Particle Immunogens for Improving CD8+ T-Cell Responses X He , S Zhou , B Quinn, WC Huang - Advanced , 2021 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/advs.202103023 Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2. 1 binding affinity and S Bownds, P Tong-On, SA Rosenberg - Journal of , 2001 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2001/01000/Induction_of_Tumor_Reactive_Cytotoxic.1.aspx/1000 Backbone modifications of HLA-A2-restricted antigens induce diverse binding and T cell activation outcomes R Gibadullin , CJ Randall, J Sidney - Journal of the , 2021 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/jacs.1c00016 An isolated TCR alphabeta restricted by HLA-A* 02: 01/CT37 peptide Redirecting CD8+ T cells to kill and secrete IFN-γ in response to lung adenocarcinoma cell lines PO Flores-Villanueva, M Ganachari, H Guio - The Journal of , 2018 - journals.aai.orghttps://journals.aai.org/jimmunol/article/200/8/2965/106829 Quantifying and Imaging P Vyas, JL Chen , V Cerundolo, BK Karbach, E Jager - J Immunol, 2006 - academia.eduhttps://www.academia.edu/download/68505824/7308.full.pdf Preparation of peptide-MHC and T-cell receptor dextramers by biotinylated dextran doping MT Bethune , B Comin-Anduix, YHH Fu, A Ribas - , 2018 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.2144/000114525 Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors MA Purbhoo, DH Sutton, JE Brewer - The Journal of , 2006 - journals.aai.orghttps://journals.aai.org/jimmunol/article/176/12/7308/7464 SpyAvidin hubs enable precise and ultrastable orthogonal nanoassembly M Fairhead , G Veggiani , M Lever, J Yan - Journal of the , 2014 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/ja505584f Structural and kinetic basis for heightened immunogenicity of T cell vaccines JL Chen , G Stewart-Jones, G Bossi, NM Lissin - The Journal of , 2005 - rupress.orghttps://rupress.org/jem/article-abstract/201/8/1243/52591 Ca2+ Release from the Endoplasmic Reticulum of NY-ESO-1-Specific T Cells Is Modulated by the Affinity of TCR and by the Use of the CD8 Coreceptor JL Chen , AJ Morgan, G Stewart-Jones - The journal of , 2010 - journals.aai.orghttps://journals.aai.org/jimmunol/article/184/4/1829/38714 Dual role of the peptide-loading complex as proofreader and limiter of MHC-I presentation J Brunnberg, M Barends - Proceedings of the , 2024 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.2321600121 Decoupling peptide binding from T cell receptor recognition with engineered chimeric MHC-I molecules GF Papadaki , O Ani, TJ Florio, MC Young - Frontiers in , 2023 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1116906/full Rational development of high-affinity T-cell receptor-like antibodies G Stewart-Jones, A Wadle - Proceedings of the , 2009 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.0901425106 and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1157-165 tumor-specific peptide E Shenderov , M Kandasamy, U Gileadi - for immunotherapy of , 2021 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183295/ Synthesis and evaluation of novel TLR2 agonists as potential adjuvants for cancer vaccines BL Lu, GM Williams, DJ Verdon - Journal of Medicinal , 2019 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.9b01044 TCR fingerprinting and off-target peptide identification AR Karapetyan, C Chaipan, K Winkelbach - Frontiers in , 2019 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fimmu.2019.02501/full Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor A Varela-Rohena, PE Molloy, SM Dunn, Y Li - Nature medicine, 2008 - nature.comhttps://www.nature.com/articles/nm.1779 T lymphocytes need less than 3 min to discriminate between peptide MHCs with similar TCR-binding parameters A Brodovitch, E Shenderov , V Cerundolo - European journal of , 2015 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/eji.201445214

Avviso:
I nostri prodotti sono destinati esclusivamente ad uso di laboratorio. Per qualsiasi altro utilizzo, vi preghiamo di contattarci.
Marchio:
Biosynth
Conservazione lunga:
Note:

Proprietà chimiche

MDL:
Punto di fusione:
Punto di ebollizione:
Punto di infiammabilità:
Densità:
Concentrazione:
EINECS:
Merck:
Codice SA:

Informazioni sui pericoli

Numero ONU:
EQ:
Classe:
Indicazioni di pericolo:
Consigli di prudenza:
Vietato trasportare in aereo:
Informazioni sui pericoli:
Gruppo di imballaggio:
LQ:

Richiesta tecnica su: 3D-PP46378 H-SLLMWITQV^-OH

Si prega di utilizzare piuttosto il carrello per richiedere un preventivo o un ordine

Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.

* Campi obbligatori
Benvenuto su CymitQuimica!Utilizziamo i cookie per migliorare la tua visita. Non includiamo pubblicità.

Consulta la nostra Politica sui Cookie per maggiori dettagli o regola le tue preferenze in "Configura".